10-K · April 28, 2026
Lisata reports modest operational signs of stabilization (revenue of $100,000 in 2025Q4 and diluted EPS improving to -$0.33) but remains a loss-making, cash‑burning clinical-stage company (free cash flow -$3.0M in…
Earnings analysis · 10-Q
LSTA earnings analysis
Filed May 11, 2026 · Our reading of the company's report
The latest report
Lisata Therapeutics reported a net loss of $4.49 million for Q1 2026, a slight improvement from a loss of $4.72 million in Q1 2025. Operating expenses decreased by 15.5% to $4.94 million, driven by reduced R&D costs.…
Read full summary
Lisata Therapeutics reported a net loss of $4.49 million for Q1 2026, a slight improvement from a loss of $4.72 million in Q1 2025. Operating expenses decreased by 15.5% to $4.94 million, driven by reduced R&D costs. The company continues to seek additional funding amid significant liquidity challenges, with $13.1 million in cash on hand as of March 31, 2026.
Reported figures
- Earnings per share
- $-0.62
What stood out
-
Improved Net Loss
Net loss reduced to $4.49 million in Q1 2026 from $4.72 million a year ago.
-
Decrease in Operating Expenses
Operating expenses declined by 15.5% to $4.94 million, down from $5.85 million.
-
Cash Position
Cash and cash equivalents available were approximately $13.1 million as of March 31, 2026.
-
Research Expenses Cut by 53.7%
R&D expenses fell to $1.2 million from $2.6 million for the same period last year.
-
Legal and Consulting Fees Increase
General and administrative expenses rose by 15.2% to $3.7 million, reflecting increased legal costs.
-
Cash Used in Operations Improves
Cash used in operating activities decreased, totaling $3.1 million, down from $5.4 million in the previous year.
What to watch
-
Merger Uncertainty
The proposed acquisition by Kuva is pending, with no guarantee of closure by the May 29, 2026 deadline.
-
Ongoing Liquidity Challenges
Lisata faces substantial doubt about continuing operations, having to secure additional funding.
-
Potential Shareholder Distrust
Failure to complete the merger could lead to a decline in investor confidence and stock price.
Management's outlook
No explicit guidance provided in the filing; Management anticipates potential capital needs.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.